Business Context and Reporting Period
ImmunityBio, Inc. (IBRX) is a vertically-integrated commercial-stage biotechnology company focused on developing next-generation immunotherapies. The reporting period covers the fiscal year ended December 31, 2024. The company's primary commercial asset is ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 receptor superagonist approved by the FDA on April 22, 2024, for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Commercial distribution began in May 2024.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $14.7 million | $0.6 million |
| Product Revenue (ANKTIVA) | $14.2 million | $0 |
| Net Loss | $(413.6) million | $(583.9) million |
| Operating Expenses | $358.9 million | $362.9 million |
| Cash and Cash Equivalents | $143.4 million | $265.5 million |
| Marketable Securities | $6.4 million | $1.0 million |
| Total Debt & Revenue Interest Liability | ~$746.3 million | ~$732.4 million |
Note: Total Debt includes a $505.0 million related-party convertible note and a $284.4 million revenue interest liability. The company reported an accumulated deficit of $3.4 billion as of December 31, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 2,271% year-over-year, driven entirely by the commercial launch of ANKTIVA in the second half of 2024. Prior to April 2024, the company had no product revenue.
- Net Loss Reduction: Net loss decreased by 29% to $413.6 million, primarily due to a $79.7 million favorable change in the fair value of related-party convertible notes and a $67.6 million reduction in the fair value of warrant liabilities.
- Expense Management: Research and Development (R&D) expenses decreased by 18% ($42.2 million) due to reduced external clinical trial costs and CMO fees. Selling, General, and Administrative (SG&A) expenses increased by 30% ($39.2 million), largely driven by a $10.5 million legal settlement expense and increased commercial readiness costs.
- Liquidity: Cash and cash equivalents decreased by $122.1 million, reflecting operating cash outflows of $391.2 million, partially offset by $281.6 million in financing activities (including RIPA proceeds and warrant exercises).
Guidance, Outlook, and Risks
Outlook and Catalysts:
- RMAT Designation: On February 27, 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for ANKTIVA combined with PD-L1 t-haNK for the reversal of lymphopenia and treatment of metastatic pancreatic cancer.
- Commercial Expansion: The company received a permanent J-code (J9028) for ANKTIVA effective January 1, 2025, facilitating reimbursement. Unit sales volume grew 97% in February 2025 compared to December 2024.
- Global Submissions: Marketing Authorization Applications (MAAs) were submitted to the EMA (EU) and MHRA (UK) in late 2024, with potential approval targeted for 2026.
- Pipeline: The company plans to submit a Biologics License Application (BLA) for ANKTIVA in NSCLC and for the reversal of lymphopenia in 2025.
Key Risks and Contingencies:
- Liquidity and Going Concern: The company states substantial doubt exists regarding its ability to continue as a going concern without additional funding. It relies on existing cash, product sales, and the intent of its Founder/Executive Chairman to provide additional support.
- Debt Obligations: The company has significant debt obligations, including a $505.0 million convertible note and a Revenue Interest Purchase Agreement (RIPA) requiring quarterly payments based on net sales (tiered 4.5% to 10.0%). Failure to meet RIPA covenants could trigger a "True-Up Payment" or foreclosure.
- BCG Shortage: Commercial success of ANKTIVA is dependent on the availability of BCG. The company is addressing this via an Expanded Access Program (EAP) with Serum Institute to supply recombinant BCG (rBCG).
- Legal Proceedings: The company agreed to settle a securities class action for $10.5 million (recorded in 2024). Several shareholder derivative actions remain pending regarding related-party transactions and prior FDA communications.
Investor Verification Checklist
- Reimbursement Status: Verify the actual uptake of the new J-code (J9028) and the breadth of commercial/governmental insurance coverage for ANKTIVA.
- BCG Supply Chain: Confirm the timeline and regulatory status of the rBCG supply agreement with Serum Institute to mitigate TICE BCG shortages.
- Debt Covenants: Review the specific covenants in the RIPA and the $505 million convertible note to assess the risk of default or forced equity conversion.
- Cash Burn Rate: Monitor quarterly cash flow statements to determine if the current cash balance ($149.8 million) is sufficient to fund operations through the next 12 months without additional capital raises.
- Legal Settlements: Track the status of the $10.5 million securities class action settlement approval and the outcome of pending shareholder derivative lawsuits.